These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23863802)

  • 1. CYP3A5 polymorphism, amlodipine and hypertension.
    Zhang YP; Zuo XC; Huang ZJ; Cai JJ; Wen J; Duan DD; Yuan H
    J Hum Hypertens; 2014 Mar; 28(3):145-9. PubMed ID: 23863802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
    Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
    Cai J; Huang Z; Yang G; Cheng K; Ye Q; Ming Y; Zuo X; Zhou P; Yuan H
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):401-9. PubMed ID: 22149319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism.
    Lu Y; Zhong H; Tang Q; Huang Z; Jing N; Smith J; Miao R; Li Y; Yuan H
    Mol Med Rep; 2017 Apr; 15(4):1593-1600. PubMed ID: 28259948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
    Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
    Bhatnagar V; Garcia EP; O'Connor DT; Brophy VH; Alcaraz J; Richard E; Bakris GL; Middleton JP; Norris KC; Wright J; Hiremath L; Contreras G; Appel LJ; Lipkowitz MS;
    Am J Nephrol; 2010; 31(2):95-103. PubMed ID: 19907160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
    Torio A; Auyanet I; Montes-Ares O; Guerra RM; Fernandez EJ; Perez MA; Ramirez A; Checa MD
    Transplant Proc; 2012 Nov; 44(9):2596-8. PubMed ID: 23146466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
    Kim KA; Park PW; Park JY
    Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
    Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
    Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
    Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
    Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.
    Xi B; Wang C; Liu L; Zeng T; Liang Y; Li J; Mi J
    Hypertens Res; 2011 Nov; 34(11):1216-20. PubMed ID: 21814220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.
    Coto E; Tavira B; Marín R; Ortega F; López-Larrea C; Ruiz-Ortega M; Ortiz A; Díaz M; Corao AI; Alonso B; Alvarez V
    Biochem Biophys Res Commun; 2010 Jul; 397(3):576-9. PubMed ID: 20617557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men.
    Zhang L; Miyaki K; Wang W; Muramatsu M
    J Hum Hypertens; 2010 May; 24(5):345-50. PubMed ID: 19812606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy.
    Lieb W; Bolbrinker J; Döring A; Hense HW; Erdmann J; Schunkert H; Kreutz R
    Clin Sci (Lond); 2006 Dec; 111(6):365-72. PubMed ID: 16822233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.
    Zuo XC; Zhang WL; Yuan H; Barrett JS; Hua Y; Huang ZJ; Zhou HH; Pei Q; Guo CX; Wang JL; Yang GP
    Drug Metab Pharmacokinet; 2014; 29(4):305-11. PubMed ID: 24522199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population.
    Fisher DL; Plange-Rhule J; Moreton M; Eastwood JB; Kerry SM; Micah F; Johnston A; Cappuccio FP; MacPhee IA
    J Hum Hypertens; 2016 Dec; 30(12):778-782. PubMed ID: 27334520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.
    Zuo XC; Zhou YN; Zhang BK; Yang GP; Cheng ZN; Yuan H; Ouyang DS; Liu SK; Barrett JS; Li PJ; Liu Z; Tan HY; Guo R; Zhou LY; Xie YL; Li ZJ; Li J; Wang CJ; Wang JL
    Drug Metab Pharmacokinet; 2013; 28(5):398-405. PubMed ID: 23438946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP3A5 and ABCB1 genes and hypertension.
    Bochud M; Bovet P; Burnier M; Eap CB
    Pharmacogenomics; 2009 Mar; 10(3):477-87. PubMed ID: 19290795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
    Wang L; Li N; Wang MX; Lu SC
    Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.